CervoMed Inc. (CRVO)
CRVONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.75
-0.0250 (-1.41%) today
Regular session, Nov 12, 12:45 PM ET
- Market cap
- $26.40m
- P/E
- –
- EPS, last 4 quarters
- $-2.77
- Dividend yield
- –
- Day range
- $1.73 to $2.17
- 52-week range
- $1.27 to $10.00
- Average volume
- –
- Previous close
- $1.77
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $15.25, +773.9% from here
Earnings
next estimate $-0.5500Next report
Dec 2025
-11.4%
Mar 2026
+4.4%
Jun 2026
+26.4%
Sep 2026
+36.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $323.0k | $9,000 | – | – |
| Gross profit | $323.0k | $9,000 | – | – |
| Operating income | -$8.04m | -$8.33m | -$8.11m | -$6.68m |
| Net income | -$7.73m | -$8.09m | -$7.96m | -$6.57m |
News
8 latest- CervoMed Inc. Reports Third Quarter 2026 Financial ResultsFintel · 3 days ago
- Agenus (AGEN) Q3 Earnings Meet EstimatesZacks · 7 days ago
- CervoMed Inc. Announces Publication of Two Peer-Reviewed Research Articles Supporting NeflamapimodFintel · Oct 30, 2026
- CervoMed Reports Initial NfL Findings; Clinical Data Expected In Q1 2027 RTTNews · Oct 12, 2026
- CervoMed Reports NfL Biomarker Decline In Phase 2a Neflamapimod Trial RTTNews · Oct 12, 2026
- CervoMed Advances Neflamapimod With New Tablet Formulation And FDA Dose Flexibility RTTNews · Sep 28, 2026
- CervoMed Presents Initial Phase 2a Results Of Neflamapimod In NfvPPA; Data Accepted For ISFTD 2026 RTTNews · Sep 10, 2026
- Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 6, 2026
The company
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed's Phase 2b RewinD-LB clinical trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed reported initial 12-week biomarker data from its ongoing Phase 2a clinical trial in nfvPPA in October 2026 and expects to present 24-week biomarker data at CTAD 2026 in mid-November 2026.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cervomed.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.